**In Vitro: Evaluation of Inhibitory Activity of Some Plant Extracts Against Oral Candidiasis**

Mohamed A. Fareid

Botany and Microbiology Dept., Faculty of Science, Al-Azhar University

Present address: Medical Microbiology Dept., Faculty of Medicine, H’ail University, SA.

mohamedfareid73@yahoo.com

**Abstract**: Six ethanolic extracts from plants of Ginger (*Zingiber officinale*), Cinnamon (*Cinnamomum verum*), Black Cumin (*Nigella sativa*), Clove (*Syzygium aromaticum*), Black Pepper (*Piper nigrum*), and Chamomile (*Anthemis nobilis*) were purchased from local market in H’ail province, Saudi Arabia wereassayed for the in vitro inhibitory activity againstsome oral Candidal isolates. The prevalence of oral candidalinfections among poor control diabetes patients was higher (56%) than fair control (30%) and good control (7%) diabetes patients. Statistically, our data indicated that a higher significant difference between the prevalence of oral candidiasis and diabetic control (p-value = 0.001). Cinnamon and Clove plant extracts were the most effective of all pathogenic yeasts studied. *Candida albicans, C. parapsilosis and C tropicalis* showed greatest degree of sensitivity to Cinnamon and Clove plant extracts. The inhibition zone diameter recorded 34.6, 31.5; 45, 31; 45.5, 29.5 mm, respectively at 100 µg/ml concentration.Based on paired t-test, there is no significant difference between the mean values of the inhibition zone size of Amphotericin B, Black cumin, Chamomile and plant extracts were reported (P-value ˂ 0.05). Both Cinnamon and Clove extracts showed remarkable effect on *C. albicans* and *C. tropicalis* at very low concentration MIC, 15, 18 and 15, 19 μl/ml, respectively.

[Mohamed A. Fareid. **In Vitro: Evaluation of Inhibitory Activity of Some Plant Extracts Against Oral Candidiasis.** *N Y Sci J* 2014;7(12):66-76]. (ISSN: 1554-0200). <http://www.sciencepub.net/newyork>. 9

**Keywords:** Inhibitory activity, Plant extracts, Oral, Candidiasis.

**1. Introduction**

Due to the increasing development of drug resistance in human pathogens as well as the appearance of undesirable effect of certain antimicrobial agents, there is a need to search for new antifungal agents without toxicity and side effects. Therefore it is necessary to search for more effective and less toxic novel antifungal agents that would overcome these disadvantages. Infection with the yeast like fungal organism *Candida albicans* is termed as candidiasis (Navejesh and Brightman, 1995). In recent years, there has been a significant increase in the incidence of human fungal infections (Lass-Flörl, 2009). A number of factors have been implicated with this increase, but it is generally accepted that the main influences relate to the more widespread provision of new medical practices, such as immunosuppressive therapy and use of broad spectrum antibiotics, and invasive surgical procedures such as solid organ or bone marrow transplantation. Infections may either be superficial, affecting the skin, hair, nails and mucosal membranes, or systemic, involving major body organs (Ruping *et al*., 2008). Of the fungi regarded as human pathogens, members of the genus Candida are amongst the most frequently recovered from disease.

Oral candidiasis is one of the common fungal infections affecting the oral mucosa. Oral fungal disease commonly encountered within general dental practice is oral candidiasis (Farah *et al*., 2010). These infections are most frequently caused by *Candida albicans*, but other species such as *Candida glabrata Candida tropicalis Candida parapsilosis Candida krusei* and *Candida* *dubliniensis* are also responsible (Thompson *et al*., 2010; Akpan and Morgan 2002). Diabetes mellitus is a chronic disease frequently associated with many risk factors (Lorenzo and Haffner, 2010; Craig *et al*., 2009; Dodds *et al*., 2000). It is a syndrome of abnormal carbohydrate, fat and protein metabolism due to the decreased insulin secretion or/and disturbed insulin activity. Diabetes mellitus has been related to numerous oral complications, such as periodontal disease, decreased function of salivary glands (xerostomia), burning mouth sensation and oral candidiasis (Lamster *et al*., 2008; Samaranayake and Leung, 2000; Guggenheimer *et al*., 2000).

Amphotericin B has been provided for the standard treatment of the most systemic fungal infections (Medoff and Kobayashi, 1980). Unfortunately, treatment with Amphotericin B, especially for long-term periods, can lead to adverse effects in patients or to the development of resistant organisms during the course of therapy (Kovacicova *et al*., 2001). In the quest for new antifungal agents, low toxicity and broad spectrum fungicidal activities are needed for effective management of the infections. Triazole antifungal agents, such as Fluconazole and Itraconazole, are considered to be first-choice agents for treatment and prevention because of their relatively low side effects and high effectiveness on mucosal infections. However, with prolonged exposure to azoles, drug resistance becomes a challenge for clinicians and patients alike.

Due to the presence and increase of numerous drug resistant strains, there is an urgent need to develop novel antimicrobial agents; hence, much attention has been made on medicinal plants during the last decade (Fani *et al*., 2007; Pesewu *et al*., 2008; Aqil *et al*., 2005; Martin and Ernst, 2003). Crude extracts from a number of medicinal herbs have been shown to exhibit antifungal activities *in vitro* (Liu *et al*., 2011; Alsaidy, 2014; Doudi *et al.,* 2014). The oil extract of green tea (*Camellia sinensis*) (Hirasawa *et al*., 2002), garlic (*Allium sativum*) (Fani *et al*., 2007; Martin and Ernst, 2003), Cinnamon (*Cinnamon zeylanicum*) (Senhaji, *et al*., 2007), *Eucalyptus globulus* (Salari *et al*., 2006), *Zataria multiflora* (Khosravi *et al*., 2008), *Artemizia feddei* (Cha *et al*., 2007), and Rosmary (*Rosmarious officinalis*) (Luqman *et al*., 2007), were the most extensively researched medicinal plants which have been reported to have inhibitory activity on various bacterial, fungal and viral agents. The current study aimed to investigate the frequency of oral candidiasis in diabetic and non-diabetic patients, as well as the association between the frequency of oral candidiasis and some risk factors. In addition to evaluate the inhibitory activity of some plant extracts against the isolated Candida species.

**2. Materials And Methods**

**2.1. Sample collection and cultivation**

Sixty five Candidal isolates were obtained from one hundred seventy five patients (sixty two diabetics and one hundred thirteen non-diabetics) who had attended private dental clinics, in H’ail province, Saudi Arabia. Samples were mainly collected from the buccal mucosa, tongue and hard palate by using sterile cotton swabs. These swabs were cultivated on the Sabouraud dextrose agar (SDA) plates and placed in the incubator for 48-72 hr at 37 °C. The growth was stained and identified.

**2.2. Identification of isolates**

Candidal isolates were identified by classical methods using the following biochemical tests: Fermentation of D-glucose, assimilation of carbohydrates D-galactose, maltose, sucrose, cellobiose, trehalose, raffinose, melezitose, soluble starch, L-arabinose and germ tube formation (Brown and Gow, 1999), hyphae/pseudohyphae (Kurtzman and Fell, 1998) and chlamydospores production (Taschdjian, 1957). Carbohydrate fermentation and urea hydrolysis were carried out by subculture of 2-3 representative colonies on CHROMagar *Candida* medium (CHROMagar, Paris, France). The plates were incubated at 37°C for 48-72 hr. Also, the identification of Candidal isolates was confirmed by using the API 20C *Candida* identification system (Bio-Merieux, Marcy I’Etoile, France).

**2.3. HbA1C level**

HbA1C level was determined in capillary whole blood or venous whole blood using an immunoturbidimetric assay (DCA 2000 HbA1C System, Bayer. Denmark). The validity of this assay has previously been tested (Mortensen *et al*., 1994).

**2.4. Plant material**

Six plants were used Ginger (*Zingiber officinale*), Cinnamon (*Cinnamomum verum*), Black Cumin (*Nigella sativa*), Clove (*Syzygium aromaticum*), Black Pepper (*Piper nigrum*), and Chamomile (*Anthemis nobilis*) they were purchased from a local market in H’ail city, Saudi Arabia. The plants were brought to the laboratory andthoroughly washed in distilled water and dried in shade at room temperature, then stored in a plastic bag at 4 oC until use.

**2.5. Preparation of plant extract**

Ethanolic extract of Ginger (*Zingiber officinale*), Cinnamon (*Cinnamomum verum*), Black Cumin (*Nigella sativa*), Clove (*Syzygium aromaticum*), Black Pepper (*Piper nigrum*), and Chamomile (*Anthemis nobilis*) plants were extracted according to the method described by Okogun (2000) with slight modifications. A 50 g sample of each plant was air-dried, ground into powder using an electric blender (National MX4911V, Matsushita electronics). The blended material was transferred into a beaker and 10 ml of 95% ethanol was added at ambient temperature (28 ±2°C). The mixture was extracted by agitation on a rotary shaker. Extraction was allowed to proceed for 48 hr. The mixture was decanted and the solvent was removed by evaporation at room temperature (28 ±2°C) to obtain the extract. The extracts were kept in sterile bottle at 4 oC until use.

**2.6. In vitro antifungal assay**

The antimicrobial assay was performed using the agar diffusion method of Collins *et al.* (1995) with slight modifications. The test organisms were inoculated on Sabouraud dextrose agar (SDA) plates and spread uniformly using a sterile glass spreader. Wells of 5 mm diameter were made on the Sabouraud dextrose agar using a sterile cork borer. The cut agar disks were carefully removed by the use of sterilized forceps. To each well was introduced various concentrations (0, 25, 50, 75 and 100 µg/ml) of the extracts. Control experiments comprising inoculums without plant extract were set up. The plates were allowed to stand for one hour at room temperature (25 ±2°C) for diffusion of the substances to proceed before the growth of organisms commenced. The plates were incubated at 37°C for 48-72 hr. The zones of inhibition were then measured and recorded in mm diameter.

**2.7. Determination of minimum inhibitory concentration (MIC) of ethanolic plant extracts on Candidal growth.**

Plant extracts that inhibited the growth of Candida isolates (*Candida albicans, C. glabrata, C. krusei, C. guillermondii*, *C. parapsilosis* and *C. tropicalis*) were investigated to determine the MICs using a broth-microdilution method. The Candida isolates were cultured overnight on mueller-hinton agar and then re-suspended in 1 ml mueller-hinton broth (OXOID CM 405) to obtain a final concentration of 100 CFU ml. Each extract was serially diluted with muellerhinton broth using methods approved by the National Committee for Clinical Laboratory Standards (M27-A) (NCCLS, 1997). After incubation, the MIC was determined as the lowest concentration of extract for which there was no visible.

**2.8. Statistical analysis**

The statistical SPSS version 15 was used in data analysis. All the parameters measured were expressed as means ± standard deviation. The difference between mean values was analyzed by Student's *t* test at the 5 % significance level. The confidence interval used for all statistical analyses was 95%. *P*-values less than 0.05 were significant.

**3. Results**

Sixty five Candida isolates were obtained from one hundred seventy five patients (sixty two diabetics and one hundred thirteen non-diabetics) who had attended private dental clinics, in H’ail province, Saudi Arabia. The isolated pathogens were *Candida albicans, C. glabrata, C. krusei, C. guillermondii*, C*. parapsilosis* and *C. tropicalis.* Out of a total six ethanolic plant extracts (Ginger, Cinnamon, Black cumin, Clove, Black pepper and Chamomile) (Table 1) were tested for their *in vitro* inhibitory activities against all isolated Candida species. Our results indicated that *Candida albicans* was in higher frequency between the isolated pathogens and followed by *C. tropicalis*. They recorded 38.46% and 24.62%, respectively, while *C. gullermondii* was in lower frequency. It recorded 3.08% of the total percentage of the isolated pathogens (Figure 1).

**Table (1): Common and scientific names of some plants used to detect their antifungal activities in vitro.**

|  |  |  |  |
| --- | --- | --- | --- |
| **Common name** | **Scientific name** | **Family** | **Used part** |
| Ginger | *Zingiber officinale* | Zingiberaceae | Dried rhizome |
| Cinnamon | *Cinnamomum* *cassia* | Lauraceae | Dried barks |
| Black cumin | *Nigella sativa* | Myrtaceae | Dried seeds |
| Clove | *Syzygium* *aromaticum* | Myrtaceae | Dried buds |
| Black pepper | *Piper nigrum* | Piperaceae | Dried fruits |
| Chamomile | *Anthemis nobilis* | **Compositae** | Dried Flowers |

**Figure 1. Frequency percentage of isolated pathogens.**

**3.1. Association between the frequency of oral candidiasis and some risk factors.**

Table (2) represents the incidence of oral candidiasis in relation to the risk factors. A higher percentage of oral candidiasis(41.5%) was found within the age brackets of 30-39 years while age groups 20-29 years had the least percentage (13.8%). Also, highest number of oral candidiasis was obtained from smoking (68%) than from non-smoking patients (32%). In addition to smoking, diabetic control level showed a lower number of oral candida infection in HBA1C good control patients (14%), while a higher number of oral candida infections were detected in HBA1C poor control patients (56%). Statistically, our results were showed a highly significant difference between prevalence of oral candidiasis and all tested risk factors (P*-*value < 0.05) except in sex factor there is no significant difference (P*-*value > 0.05).

**Table (2): Association between the frequency of oral candidiasis and some risk factors.**

|  |  |  |
| --- | --- | --- |
| **Characteristics** | **Frequency of Oral Candidiasis** | ***P*-value** |
| **No.** | **%** |
| **Age group (years)**20-2930-3940-4950-59 | 9271910 | 13.841.529.215.4 | 0.004 |
| **Six**MaleFemale | 3837 | 52.3147.69 | 0.709 |
| **Smoking**CurrentNever/ Former | 3416 | 6832 | 0.010 |
| **HBA1c level**Good control (6.5-7.5 %).Fair control (8 -9.5 %).Poor control (˃ 9.5 %). | 71528 | 143056 | 0.001 |

**3.2. Susceptibility of *C. albicans* to different concentrations of some plant extracts.**

Out of a total 6 ethanolic plant extracts (Ginger, Cinnamon, Black cumin, Clove, Black pepper and Chamomile) were tested for their *in vitro* inhibitory activities against *Candida albicans*. Our results showed that Cinnamon and Clove were recorded higher inhibitory activity at 100 µg/ml concentration. The inhibition zone recorded 34.6 and 31.5 mm, respectively, while Black cumin and Chamomile were recorded a lower inhibitory activity at the same concentration. The inhibition zone recorded 20.3 mm (Table 3). Statistically, our data exhibit a highly significant difference between all concentrations of all plant extracts (P*-*value < 0.05).

**Table (3): Susceptibility of *C. albicans* to different concentrations of some plant extracts.**

|  |  |
| --- | --- |
| **Plant name** | **Inhibition zone (mm) ± SD at different concentrations of plant extracts** |
| **Control** | **25 µg/ml** | **50 µg/ml** | **75 µg/ml** | **100 µg/ml** | **t-Test** |
| Ginger | 0.0 | 14.1 ±0.2 | 16.6 ±0.4 | 19.1 ±0.5 | 24.0 ±0.6 | 0.003 |
| Cinnamon | 0.0 | 15.6 ±0.4 | 20.0 ±0.6 | 27.5 ±0.3 | 34.6 ±0.4 | 0.010 |
| Black cumin | 0.0 | 10.3 ±0.4 | 13.0 ±0.6 | 16.6 ±0.4 | 20.3 ±0.8 | 0.006 |
| Clove | 0.0 | 12.0 ±0.6 | 16.6 ±0.8 | 22.5 ±0.3 | 31.5 ±0.3 | 0.014 |
| Black pepper | 0.0 | 11.6 ±0.4 | 17.3 ±0.4 | 23.6 ±0.4 | 30.0 ±0.6 | 0.016 |
| Chamomile | 0.0 | 10.6 ±0.4 | 13.0 ±0.6 | 17.6 ±0.8 | 20.3 ±0.4 | 0.006 |

**3.3. Susceptibility of *C. glabrata* to different concentrations of some plant extracts.**

Table (4) represents the inhibitory activity of tested ethanolic plant extracts (Ginger, Cinnamon, Black cumin, Clove, Black pepper and Chamomile) against *C. glabrata*. Cinnamon and Clove were recorded higher inhibitory activity at 100 µg/ml concentration. The inhibition zone recorded 31.5 and 24.3 mm, respectively, while Black cumin and Chamomile recorded a lower inhibitory activity at the same concentration, the inhibition zone recorded 19.5 and 18.5 mm, respectively. Statistically, our results showed that there is a highly significant difference between all concentrations of all plant extracts (P*-*value < 0.05).

**Table (4): Susceptibility of *C. glabrata* to different concentrations of some plant extracts.**

|  |  |
| --- | --- |
| **Plant name** | **Inhibition zone (mm) ± SD at different concentrations of plant extracts** |
| **Control** | **25 µg/ml** | **50 µg/ml** | **75 µg/ml** | **100 µg/ml** | **t-Test** |
| Ginger | 0.0 | 12.5 ±0.3 | 14.3 ±0.5 | 17.0 ±0.6 | 23.1 ±0.5 | 0.005 |
| Cinnamon | 0.0 | 13.0 ±0.6 | 17.6 ±0.4 | 24.8 ±0.2 | 31.5 ±0.3 | 0.013 |
| Black cumin | 0.0 | 9.5 ±0.7 | 11.1 ±0.5 | 15.5 ±0.3 | 19.5 ±0.3 | 0.009 |
| Clove | 0.0 | 11.6 ±0.5 | 16.5 ±0.3 | 20.1 ± 0.5 | 24.3 ±0.7 | 0.007 |
| Black pepper | 0.0 | 10.5 ±0.3 | 13.6 ±0.2 | 16.5 ±0.3 | 22.6 ±0.2 | 0.009 |
| Chamomile | 0.0 | 8.6 ±0.2 | 11.5 ±0.3 | 15.6 ±0.2 | 18.5 ±0.3 | 0.008 |

**3.4.** **Susceptibility of *C. krusei* to different concentrations of some plant extracts.**

Table (5) represents the susceptibility of *C. krusei* to different concentrations of some plant extracts. Our results showed that all tested ethanolic plant extracts (Ginger, Cinnamon, Black cumin, Clove, Black pepper and Chamomile) exhibit antifungal effects against *Candida krusei*. Cinnamon and Clove were recorded higher inhibitory activity at 100 µg/ml concentration. The inhibition zone recorded 35.8 and 26 mm, respectively, while Black cumin and Chamomile recorded a lower inhibitory activity at the same concentration, the inhibition zone recorded 18.7 and 19.5 mm, respectively. Statistically, our data showed that there is a highly significant difference between all concentrations of all plant extracts (P*-*value < 0.05).

**Table (5): Susceptibility of *C. krusei* to different concentrations of some plant extracts.**

|  |  |
| --- | --- |
| **Plant name** | **Inhibition zone (mm) ± SD at different concentrations of plant extracts** |
| **Control** | **25 µg/ml** | **50 µg/ml** | **75 µg/ml** | **100 µg/ml** | **t-Test** |
| Ginger | 0.0 | 13.5 ±0.3 | 15.6 ±0.2 | 17.5 ±0.3 | 22.6 ±0.4 | 0.003 |
| Cinnamon | 0.0 | 11.6 ±0.2 | 19.5 ±0.3 | 26.6 ±0.2 | 35.8 ±0.5 | 0.020 |
| Black cumin | 0.0 | 7.1 ±0.5 | 11.5 ±0.3 | 15.6 ±0.2 | 18.7 ±0.5 | 0.013 |
| Clove | 0.0 | 12.0 ±0.3 | 16.0 ±0.6 | 20.8 ±0.5 | 26.0 ±0.3 | 0.009 |
| Black pepper | 0.0 | 8.5 ±0.3 | 14.1 ±0.2 | 18.1 ±0.5 | 25.9 ±0.6 | 0.020 |
| Chamomile | 0.0 | 7.6 ±0.2 | 10.4 ±0.2 | 14.1 ±0.5 | 19.5 ±0.3 | 0.015 |

**3.5. Susceptibility of *C. guillermondii* to different concentrations of some plant extracts.**

Table (6) represents thesusceptibility of *C. guillermondii* to different concentrations of some plant extracts. Our results showed that a highly inhibitory activity to Cinnamon, Clove and Black pepper against *C. guillermondii* at 100 µg/ml concentration. The inhibition zone recorded 27.8, 28.5 and 27.5 mm, respectively, while Black cumin recorded a lower inhibition zone (18.8 mm) at the same concentration. Statistically; our data exhibit a highly significant difference between all concentrations of all plant extracts (P*-*value < 0.05).

**Table (6): Susceptibility of *C. guillermondii* to different concentrations of some plant extracts.**

|  |  |
| --- | --- |
| **Plant name** | **Inhibition zone (mm) ± SD at different concentrations of plant extracts** |
| **Control** | **25 µg/ml** | **50 µg/ml** | **75 µg/ml** | **100 µg/ml** | **t-Test** |
| Ginger | 0.0 | 12.6 ±0.6 | 15.5 ±0.3 | 17.1 ±0.2 | 22.0 ±0.6 | 0.003 |
| Cinnamon | 0.0 | 10.8 ±0.5 | 16.5 ±0.3 | 22.8 ±0.5 | 27.8 ±0.2 | 0.013 |
| Black cumin | 0.0 | 8.5 ±0.3 | 11.8 ±0.2 | 15.5 ±0.3 | 18.8 ±0.2 | 0.009 |
| Clove | 0.0 | 12.8 ±0.2 | 17.8 ±0.5 | 23.5 ±0.3 | 28.5 ±0.3 | 0.009 |
| Black pepper | 0.0 | 11.8 ±0.5 | 15.8 ±0.2 | 22.0 ±0.6 | 27.5 ±0.3 | 0.011 |
| Chamomile | 0.0 | 7.8 ±0.2 | 10.5 ±0.3 | 16.0 ±0.6 | 22.1 ±0.7 | 0.021 |

**3.6. Susceptibility of *C. parapsilosis* to different concentrations of some plant extracts.**

Table (7) represents the susceptibility of *C. parapsilosis* to different concentrations of some plant extracts. Our data exhibit higher inhibitory activity to Cinnamon and Clove against *C. parapsilosis* at concentration 100 µg/ml. The inhibition zone recorded 45 and 31 mm, respectively, while Black cumin recorded a lower inhibitory activity at concentration 25 and 100 µg/ml. It inhibition zone recorded 8.5 and 19.7 mm, respectively. Statistically, our data exhibit a highly significant difference between all concentrations of all plant extracts (P*-*value < 0.05).

**Table (7): Susceptibility of *C. parapsilosis* to different concentrations of some plant extracts.**

|  |  |
| --- | --- |
| **Plant name** | **Inhibition zone (mm) ± SD at different concentrations of plant extracts** |
| **Control** | **25 µg/ml** | **50 µg/ml** | **75 µg/ml** | **100 µg/ml** | **t-Test** |
| Ginger | 0.0 | 11.8 ±0.2 | 15.1 ±0.5 | 18.5 ±0.3 | 22.5 ±0.3 | 0.005 |
| Cinnamon | 0.0 | 14.6 ±1.5 | 22.3 ±0.4 | 31.8 ±0.5 | 45.0 ±0.6 | 0.023 |
| Black cumin | 0.0 | 8.5 ±0.3 | 10.7 ±0.1 | 15.5 ±0.3 | 19.7 ±0.1 | 0.012 |
| Clove | 0.0 | 11.7 ±0.1 | 15.5 ±0.3 | 22.8 ±0.5 | 31.0 ±0.6 | 0.018 |
| Black pepper | 0.0 | 11.5 ±0.3 | 15.5 ±0.3 | 19.0 ±0.6 | 27.3 ±0.4 | 0.012 |
| Chamomile | 0.0 | 8.5 ±0.3 | 11.0 ±0.6 | 16.6 ±0.2 | 21.5 ±0.3 | 0.016 |

**3.7. Susceptibility of *C. tropicalis* to different concentrations of some plant extracts.**

Table (8) represents thesusceptibility of *C. tropicalis* to different concentrations of some plant extracts. Our data showed that the inhibitory activity of tested ethanolic plant extracts (Ginger, Cinnamon, Black cumin, Clove, Black pepper and Chamomile) against *C. tropicalis*. Our results exhibit higher inhibitory activity to Cinnamon and Clove at concentration 100 µg/ml. The inhibition zone recorded 45.5 and 29.5 mm, respectively, while Black cumin and Chamomile were recorded a lower inhibitory activity at the same concentration, the inhibition zone recorded 22.1 and 21.1 mm, respectively. Statistically, our data exhibit a highly significant difference between all concentrations of all plant extracts (P*-*value < 0.05).

**Table (8): Susceptibility of *C. tropicalis* to different concentrations of some plant extracts.**

|  |  |
| --- | --- |
| **Plant name** | **Inhibition zone (mm) ± SD at different concentrations of plant extracts** |
| **Control** | **25 µg/ml** | **50 µg/ml** | **75 µg/ml** | **100 µg/ml** | **t-Test** |
| Ginger | 0.0 | 12.8 ±0.5 | 16.0 ±0.6 | 19.5 ±0.3 | 24.6 ±0.4 | 0.005 |
| Cinnamon | 0.0 | 15.2 ±0.8 | 22.0 ±0.6 | 40.0 ±0.3 | 45.5 ±0.3 | 0.023 |
| Black cumin | 0.0 | 6.8 ±0.2 | 11.0 ±0.6 | 14.8 ±0.5 | 22.1 ±0.5 | 0.024 |
| Clove | 0.0 | 11.1 ±0.5 | 16.0 ±0.6 | 21.3 ±0.4 | 29.5 ±0.3 | 0.014 |
| Black pepper | 0.0 | 10.0 ±0.6 | 16.0 ±0.6 | 21.0 ±0.6 | 24.8 ±0.5 | 0.011 |
| Chamomile | 0.0 | 7.1 ±0.2 | 11.1 ±0.8 | 16.5 ±0.3 | 21.1 ±0.2 | 0.020 |

**3.8. The inhibition zone diameters of the tested isolates against different antifungal agents.**

Table (9) represents the inhibition zone diameters shown by the antifungal agents on the Candida isolates, there were varying degree of inhibition of all the isolates used in the study. The species of *C. albicans, C tropicalis* were shown resistance towards Clotrimazole and Voriconazole, respectively. Whereas, *C.krusei* and *C glabrata* were sensitive towards all the azoles except itracnozole and flucanozole, respectively. *Candida parapsilosis* was exhibit sensitive to all tested antifungal agents. None of the Candidaspecies was shown resistance towards Amphotericin B.

**Table (9): The inhibition zone diameters of the tested isolates against different antifungal agents.**

|  |  |
| --- | --- |
| Candida isolates | Inhibition zone of tested Candida isolates (mm) |
| Fluconazole | Itraconazole | Amphotericin B | Clotrimazole | Voriconazole |
| *C. albicans* | 16.6±0.8 S | 16.1±0.2 S | 20.3±0.4 S | 14.0 ±1.3 R | 26.0 ±0.6 S |
| *C. glabrata* | 12.0±0.6 R | 16.0±0.6 S | 22.0±0.6 S | 15.6 ±1.7 S | 23.3 ±1.7 S |
| *C. krusei* | 15.0±0.6 S | 12.5±0.3 R | 17.6±0.4 S | 22.6 ±0.4 S | 14.0 ±0.6 S |
| *C. guillermondii* | 10.5±0.3 R | 16.3±0.4 S | 22.3±0.4 S | 17.6 ±1.5 S | 23.0 ±1.3 S |
| *C. parapsilosis* | 24.0±0.3 S | 15.0±0.6 S | 19.0±0.6 S | 21.0 ±1.3 S | 29.3 ±1.1 S |
| *C. tropicalis* | 15.6±0.4 S | 14.0±0.3 S | 20.8±0.5 S | 18.0 ±0.6 S | 12.0 ±1.3 R |

**R, Resistance; S, Sensitive.**

**3.9. Paired Samples t-Test of anti-fungal agents and ethanolic extracts of some plant species.**

To test the hypothesis of no difference or no relationship between the size of inhibition zone of antifungal drugs and all tested ethanolic plant extracts paired t-test was performed (Table 10). For nine pairs, 30% of pairs rejected null hypothesis in favor of alternate hypothesis, there is no significant difference between the mean values of Amphotericin B, Black cumin and Chamomile inhibition zone (P*-*value > 0.05). Itraconazole was significantly related to all tested ethanolic plant extracts (P*-*value < 0.05), while Voriconazole was showed no significant difference to all tested ethanolic plant extract except with cinnamon and clove.

**Table (10): Paired Samples t-Test of anti-fungal agents and ethanolic extracts of some plant**

|  |
| --- |
| **Paired Samples Test** |
|  |  |  | **t** | **Sig. (2-tailed)** | **Decision (α = 0.05)** |
| **Pair 1** | Fluconazole | Ginger | 3.886 | 0.012 | Significance |
| **Pair 2** | Fluconazole | Cinnamon | 11.315 | 0.000 | Significance |
| **Pair 3** | Fluconazole | Black cumin | 2.255 | 0.074 | Non-significance |
| **Pair 4** | Fluconazole | Clove | 8.530 | 0.000 | Significance |
| **Pair 5** | Fluconazole | Black pepper | 5.637 | 0.002 | Significance |
| **Pair 6** | Fluconazole | Chamomile | 2.621 | 0.047 | Significance |
| **Pair 7** | Itraconazole | Ginger | 10.703 | 0.000 | Significance |
| **Pair 8** | Itraconazole | Cinnamon | 6.647 | 0.001 | Significance |
| **Pair 9** | Itraconazole | Black cumin | 6.751 | 0.001 | Significance |
| **Pair 10** | Itraconazole | Clove | 11.317 | 0.000 | Significance |
| **Pair 11** | Itraconazole | Black pepper | 10.600 | 0.000 | Significance |
| **Pair 12** | Itraconazole | Chamomile | 7.419 | 0.001 | Significance |
| **Pair 13** | Amphotericin B | Ginger | 3.461 | 0.018 | Significance |
| **Pair 14** | Amphotericin B | Cinnamon | 4.897 | 0.004 | Significance |
| **Pair 15** | Amphotericin B | Black cumin | 0.585 | 0.584 | Non-significance |
| **Pair 16** | Amphotericin B | Clove | 5.634 | 0.002 | Significance |
| **Pair 17** | Amphotericin B | Black pepper | 4.325 | 0.008 | Significance |
| **Pair 18** | Amphotericin B | Chamomile | 0.194 | 0.854 | Non-significance |
| **Pair 19** | Clotrimazole | Ginger | 3.241 | 0.023 | Significance |
| **Pair 20** | Clotrimazole | Cinnamon | 6.866 | 0.001 | Significance |
| **Pair 21** | Clotrimazole | Black cumin | 1.105 | 0.319 | Non-significance |
| **Pair 22** | Clotrimazole | Clove | 5.553 | 0.003 | Significance |
| **Pair 23** | Clotrimazole | Black pepper | 4.623 | 0.006 | Significance |
| **Pair 24** | Clotrimazole | Chamomile | 1.761 | 0.139 | Non-significance |
| **Pair 25** | Voriconazole | Ginger | 0.630 | 0.556 | Non-significance |
| **Pair 26** | Voriconazole | Cinnamon | 3.513 | 0.017 | Significance |
| **Pair 27** | Voriconazole | Black cumin | 0.473 | 0.656 | Non-significance |
| **Pair 28** | Voriconazole | Clove | 2.764 | 0.040 | Significance |
| **Pair 29** | Voriconazole | Black pepper | 2.014 | 0.100 | Non-significance |
| **Pair 30** | Voriconazole | Chamomile | 0.279 | 0.791 | Non-significance |

**3.10. Minimum inhibitory concentration (μl/ml) of ethanolic plant extracts on Candida isolates growth.**

MICs of the six plant extracts (Ginger, Cinnamon, Black cumin, Clove, Black pepper and Chamomile) were calculated by using a broth-microdilution method (Table 11). Our result showed that the MIC for all plant extracts was ranged from 15-28 μg/ml.The MIC for Cinnamon recorded 15 μg/ml on *Candida albicans*, *C.* *parapsilosis* and *C. tropicalis,* while on *C. krusei* and *C. guillermondii* were recorded 24 and 25 μg/ml, respectively. Also, the MIC for Ginger, Clove and Black Pepper were recorded 20 μg/ml on *C. guillermondii* and *C.* *parapsilosis*, while recorded 20, 19 and 24 μg/ml, respectively on *C. tropicalis*, respectively.

**Table (11): Minimum inhibitory concentration (μl/ml) of ethanolic plant extracts on Candidal isolates growth.**

|  |  |
| --- | --- |
| **Candidal isolates** | **Minimum inhibitory concentration (MIC) (μl/ml)** |
| **(1)** | **(2)** | **(3)** | **(4)** | **(5)** | **(6)** |
| *C. albicans* | 18 | 15 | 25 | 18 | 19 | 26 |
| *C. glabrata* | 20 | 20 | 25 | 24 | 24 | 28 |
| *C. krusei* | 18 | 24 | 28 | 22 | 22 | 28 |
| *C. guillermondii* | 20 | 25 | 28 | 20 | 20 | 24 |
| *C. parapsilosis* | 20 | 15 | 28 | 20 | 20 | 25 |
| *C. tropicalis* | 20 | 15 | 26 | 19 | 26 | 25 |

(1), Ginger; (2), Cinnamon; (3), Black cumin; (4), Clove; (5), Black Pepper; (6), Chamomile.

**4. Discussion**

Oral candidiasis is one of the common fungal infections affecting the oral mucosa. In the current study we isolated six types of candida species in oral cavity; they are *Candida albicans, C. glabrata, C. krusei, C. guillermondii*, C*. parapsilosis* and *C. tropicalis.* Similar work carried out by Gravina *et al*. (2007) he found that there are nearly five types of candida species which are seen in the oral cavity*.* They are *Candida albicans*, *C. tropicalis*, *C. krusei*, *C. parapsilosis* and *C. guilliermondi*. Batool*, et. al*. (2011) found thatthe majority of yeast isolates from oral cavity swabs were *C. albicans* (75%), but it was often recovered in association with other yeasts, and the second most common yeast isolated in this survey was *C. glabrata.* Similarly, our results found that *Candida albicans* was in higher frequency between all isolated pathogens and followed by *C. tropicalis*. They recorded 38.46% and 24.62%, respectively. The prevalence of oral candidainfections among poor control diabetes patients was higher (56%) than fair control (30%) and good control (7%) diabetes patients. Statistically, our data indicated that a higher significant difference between the prevalence of oral candidiasis and diabetic control (p- value = 0.001).

The current study is consistent with numerous previous studies, which have shown that diabetes mellitus is a major predisposing factor to symptomatic candidiasis, oral or otherwise (Aly *et al.,* 1995; Abu-Elteen and Abu-Alteen 1998; Leon *et al.,* 2002; Khaled *et al*., 2006). This is also in agreement with numerous previous studies, which have all indicated that diabetes mellitus enhances *Candida* colonization and proliferation (Darwazeh *et al.,* 1990, Peer *et al.,* 1993, Kumar *et al.,* 2005; Gupta *et al.,* 2007; Khovidhunkit *et al.,* 2009; Mohammad *et al.,* 2009; Sashikumar *et al.,* 2010; Radmila *et al.,* 2011). In addition to diabetes mellitus, the prevalence of oral Candida infections is influenced primarily by smoking (Rindum *et al.,* 1994; Neville *et al.,* 1995; Abu-Elteen and Abu-Alteen 1998; Khaled *et al.,* 2006). It is also clear from the findings presented in this study the prevalence of oral Candidiasis between smoking patients was in higher frequency (68%) than in the non-smoking patients (16%). Statistically, our data indicated that there was a highly significant difference between the incidence of oral candidiasis and smoking (P- value = 0.010).

Muhsin *et. al.,* (2014), showed that ethanolic extract of ginger and garlic (each alone) exhibit variable level of inhibition (ranging from 9 to 20 mm) against *Staphylococcus aureus, Staphylococcus epidermidis, Klebsiella pneumonia, Streptococcus pyogens* *Pseudomonas aeruginosa and Proteus mirabilis* and this indicated that the ethanolic extraction gives better extraction than that of aqueous one. On the other hand our results indicated that ginger exhibit variable level of inhibition against *Candida albicans, C. glabrata, C. krusei, C. guillermondii, C. parapsilosis* and *C. tropicalis* (ranging from 11.8 to 14.1 mm) at plant extract concentration 25 µg/ml. Generally, our results showed a highly inhibitory activity to all tested ethanolic plant extracts against *Candida albicans, C. glabrata, C. krusei, C. guillermondii, C. parapsilosis* and *C. tropicalis* and the diameter of inhibition zones were directly proportional to the increase in the concentration of plant extracts. Statistically, our results showed a significate difference between all the different concentrations of all tested plant extracts (P*-*value < 0.05). Alsaidy (2014), indicated that oil extracts of thyme, peppermint, basil, cinnamon gave lowest growth rates in the concentration 100 mg/ml diameters growth of 3, 2, 2 and 2 mm and the highest inhibition percentages 90.0, 93.9, 92.8 and 93.3%, and the highest growth rates in concentration 20 mg/ml growth diameters 25, 20, 20 and 23 mm and minimum inhibition percentages of 16.6, 39.3, 28.5 and 23.3%, respectively, with significant differences between the concentrations (p value < 0.05). Similarly, our data indicated that ethanolic plant extract of cinnamon and clove was the most effective against all tested isolates (*Candida albicans, C. glabrata, C. krusei, C. guillermondii, C. parapsilosis* and *C. tropicalis),* the inhibition zone diameter recorded 34.6, 31.5; 31.5, 24.3; 35.8, 26.0; 27.8, 28.5; 45.0, 31.0, 45.5, 29.5 mm. respectively.

Our study showed that cinnamon plant extract at 100 μg/ml concentration, had higher inhibitory effect on the growth of all isolated Candida species. These results were consistent with Doudi *et al.* (2014)study in Iran that was performed via disk diffusion method on Candida fungus, Ibtisam (2011) study in KSA via well diffusion assay technique on Gram-positive *Staphylococus aureus* and *Bacillus subtilis*, gram-negative *Pseudomonas aeruginosa* and *Escherichia coli* and yeast represented by *Candida albicans*, Rukayadi *et al*. (2006) study in Korea using cinnamon extract on six species of Candida with micro dilution method and Lopez *et al*. (2005) study in Spain that was performed via disk diffusion method on Candida fungus.

The hypothesis of no difference or no relationship between the size of inhibition zone of antifungal drugs and all tested ethanolic plant extracts paired t-test was performed. For nine pairs, 30% of pairs rejected null hypothesis in favor of alternate hypothesis, there is no significant difference between the mean values of Amphotericin B, Black cumin and Chamomile inhibition zone (P*-*value > 0.05). Itraconazole was significantly related to all tested ethanolic plant extracts (P*-*value < 0.05), while Voriconazole was showed no significant difference to all tested ethanolic plant extract except with cinnamon and clove. Similar results obtained by Pathak (2012), he found that there is no significant difference between the mean values of the size of zone of inhibition of Amphotericin B and herbal extracts; Clotrimazole was significantly related with *Azadirachta indica* and *Murraya koenigii*, but not with *Allium sativum*, and Voriconazole shown no-significant relation with all the herbal extracts tested.

Our result showed that the MIC for all plant extracts was ranged from 15-28 μg/ml. The MIC of *Candida albicans* to cinnamon plant extract recorded 15 μl/ml. This finding is in agreement with Doudi *et. al.* (2014) study, he showed that Cinnamon essential oil had higher inhibitory effect on the growth of different strains of *Candida albicans* at 15 μg/ml. In conclusion, the present study has demonstrated that *Candida albicans* was the most common isolates among oral candida infection, also the incidence of oral candida infection between poor control diabetic patients and smokers was higher than in a good control diabetic patients and non-smokers. Ethanolic plant extract of Cinnamon and Clove were recorded higher inhibitory activity to all tested Candida species.

**Corresponding Author:**

Dr. Mohamed A. Fareid

Botany and Microbiology Department, Faculty of Science, Al-Azhar University.

**Present address:** Medical Microbiology Dept., Faculty of Medicine, H’ail University, SA.

E-mail: mohamedfareid73@yahoo.com

**References**

1. Abu-Elteen, K. H. and Abu-Alteen, R. M. (1998): The prevalence of *Candida albicans* populations in the mouths of complete denture wearers. Microbiologica, 21: 41-48.
2. Akpan, A. and Morgan, R. (2002): Oral Candidiasis. Postgrad Med J., 78: 455-459.
3. Alsaidy, D. (2014): Isolate, Diagnosis and Treatment of Yeast *Candida albicans* accompanying the human body. International Journal of Advanced Research, 2, (1): 1081-1086.
4. Aly, F. Z., Blackwell, C. C. and MacKenzie, D. A. C. (1995): Identification of oral yeast species isolated from individuals with diabetes mellitus. Mycoses, 38: 107-110.
5. Aqil, F., Khan, M. S., Owais, M. and Ahmad, I. (2005): Effect of Certain Bioactive Plant Extracts on Clinical Isolates of Beta-lactamase Producing Methicillin Resistant *Staphylococcus aureus*. J. Basic Microbiol., 45: 106-114.
6. Batool, S. N., Ablollah, R. and Fereshteh, M. (2011): Prevalence of *Candida* species in the Oral Cavity of Patients with Periodentitis. African Journal of Biotechnology, 10 (15): 2987-2990.
7. Brown, A. J. and Gow, N. A. (1999): Regulatory Networks Controlling *Candida albicans* Morphogenesis. Trends Microbiol., 7: 333-338.
8. Cha, J. D., Jung, E. K., Kil, B. S. and Lee, K. Y. (2007): Chemical Composition and Antibacterial Activity of Essential Oil from Artemisia Feddei. J. Microbiol Biotechnol., 17: 2061-2065.
9. Collins, C. H., Lyne, P. M. and Grange, J. M. (1995): Microbiological methods (7th edn) Butterwort – Heinemann Ltd. Britain. pp. 175-190.
10. Craig, M. E., Hattersley, A. and Donaghue, K. C. (2009): Definition, epidemiology and classification of diabetes in children and adolescents. Pediatric Diabetes, 10 (12): 3-12.
11. Darwazeh, A. M. G., lamey, P. J. and Samaranayake, L. (1990): The relationship between colonization, secretor status and in-vitro adhesion of *Candida albicans* to buccal epithelial cells from diabetics. J Med Microbiol., 33: 43-9.
12. Dodds, M. W., Yeh, C. K. and Johnson, D. A. (2000): Salivary alterations in type 2 (non-insulin-dependent) diabetes mellitus and hypertension. Comm Dent Oral Epidemiol, 28: 373-381.
13. Doudi, M., Setorki, M. and Hoveyda, L. (2014): Comparing theAntifungal Effects of Five Essential Oils Plants Eucalyptus, Cinnamon, Wormwood, Sagebrush and Iranian Rose Damascena on Three Standard Strains of *Candida albicans* In Vitro. IJBPAS, 3 (4): 490-500.
14. Fani, M. M., Kohanteb, J. and Dayaghi, M. (2007): Inhibitory activity of garlic (*Allium sativum*) extract on multidrug-resistant Streptococcus mutans. J Indian Soc Pedod Prev Dent., 25: 164-168.
15. Farah, C. S., Lynch, N. and McCullough, M. J. (2010): Oral fungal infections: an update for the general practitioner. Aust Dent J., 55 (1): 48-54.
16. Gravina, H. G., de Morán, E. G., Zambrano, O., Chourio, M. L., de Valero, S. R., Robertis, S. and Mesa L. (2007): Oral Candidiasis in children and adolescents with cancer. Identification of Candida.spp Med Oral Patol Oral Cir Bucal, 12: 419-423.
17. Guggenheimer, J., Moore, P. A. and Rossie, K. (2000): Insulin-dependent diabetes mellitus and oral soft tissue pathologies. II: prevalence and characteristics of Candida and Candidal lesions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 89 (5): 570-576.
18. Gupta, S., Koirala, J., Khardori, R. and Khardori, N. (2007): Infections in diabetes mellitus and hyperglycemia. Infectious Disease Clinics of North America, 21(3): 617- 638.
19. Hirasawa, M., Takada, K., Makimura, M. and Otake, S. (2002): Improvement of periodontal status by green tea catechin using a local delivery system: a clinical pilot study. J. Periodontal Res., 37: 433-438.
20. Ibtisam, M. A. (2011): Antimicrobial Activity of Ethanolic Extracts from Some Medicinal Plant. Australian Journal of Basic and Applied Sciences, 5 (11): 678-683.
21. Khaled, H. A., Mawieh, A. H. and Suleiman, A. S. (2006): Prevalence of Oral Candida Infections in Diabetic Patients. Bahrain Medical Bulletin, 28, (1): 1-8.
22. Khosravi, A. R., Eslami, A. R., Shokri, H. and Kashanian, M. (2008): *Zataria multiflora* cream for the treatment of acute vaginal candidiasis. Int J. Gynaecol Obstet., 101: 201-202.
23. Khovidhunkit, S. P., Suwantuntula, T. and Thaweboon, S. (2009): Xerostomia, hyposalivation, and oral microbiota in type 2 diabetic patients: A preliminary study. J Med Assoc Thai, 92 (9): 1220-1228.
24. Kovacicova, G., Hanzen, J. and Pisarcikova, M. (2001): Nosocomial fungemia due to Amphotericin B-resistant Candida spp. in the pediatric patients after previous neurosurgery for brain tumors. J. Infect. Chemother. 7 (1):45-48.
25. Kumar, B. V., Padshetty, N. S., Bai, K. Y. and Rao, M. S. (2005): Prevalence of *Candida* in the Oral Cavity of Diabetic Subjects. JAPI, 53: 599- 602.
26. Kurtzman, C. P. and Fell, J. W. (1998): The yeasts: a taxonomic study. 4th ed. Amsterdam: Elsevier.
27. Lamster, I. B., Lalla, E., Borgnakke, W. S. and Taylor, G. W. (2008): The relationship between oral health and diabetes mellitus. J Am Dent Assoc, 139 (5): 19-24.
28. Lass-Flörl, C. (2009): The changing face of epidemiology of invasive fungal disease in Europe. Mycoses, 52: 197–205.
29. Leon, E. M., Jacober, S. J. and Sobel, J. D. (2002): Prevalence and risk factors for vaginal *Candida* colonization in women with type 1 and type 2 diabetes. BMC Infect Dis, 2: 1-6.
30. Liu, X., Han, Y., Peng, K., Liu, Y., Li, J. and Liu, H. (2011): Effect of Traditional Chinese Medicinal Herbs on *Candida* spp. from Patients with HIV/AIDS. Adv. Dent. Res. 23 (1): 56-60.
31. Lopez, P, Sanchez, C, Batlle, R. and Nerin, C. (2005): Solid and Vapor-phase antimicrobial activities of Six essential oils, susceptibility of selected food borne bacterial and fungal strains, J Agric food chem., 53 (17): 46-69.
32. Lorenzo, C. and Haffner, S. M. (2010): Performance characteristics of the new definition of diabetes. Diabetes Care, 33 (2): 335-337.
33. Luqman, S., Dwivedi, G. R., Darokar, M. P., Kalra, A. and Khanuja, S. P. (2007): Potential of rosemary oil to be used in drug-resistant infections. Altern Ther Health Med., 13: 54-59.
34. Martin, K. W. and Ernst, E. (2003): Herbal medicines for treatment of bacterial infections: a review of controlled clinical trials. J Antimicrob Chemother., 51: 241-246.
35. Medoff, G. and Kobayashi, G. S. (1980): Strategies in the treatment of systemic fungal infections. N. Engl. J. Med. 302:145-55.
36. Mohammad H. L., Abbas A. J., Abbas F., Ehsan T. and Mohammad H. F. (2009): Candida Colonization on the Denture of Diabetic and Non-diabetic Patients. Dent Res J., 6 (1): 23-27.
37. Mortensen, H. B., Nielsen, M. R. and Christensen, E. (1994): Comparison of two new rapid assays for HbA1C determination in patients with diabetes mellitus. Ugeskr. Laeger, 156: 317-321.
38. Muhsin, D. A. and Hussein, F. M. (2014): The Antibacterial Effect of Ginger and Garlic Extracts on Some Pathogenic Bacteria Isolated from Patients with Otitis Media. International Research Journal of Medical Sciences, 2 (5): 1-5.
39. National Committee for Clinical Laboratory Standards (NCCLS)**,** (1997): Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. National Committee for Clinical Laboratory Standards,Wayne, Pa.
40. Navejesh, M. and Brightman, V. J. (1995): Relationship between salivary flow rates and *Candida albicans* counts. Oral Surg Oral Med Oral Pathol Oral Endod; 80: 284-328.
41. Neville, B., Damm, D. D. and Allen, C. M. (1995): Oral and Maxillofacial Pathology: WB Saunders, 166-169.
42. Okogun, J. I. (2000): Methods of Medicinal Plant Extract Preparation. National Institute for Pharmaceutical Research and Development (NIIPRD). Idu-Abuja, Nigeria.
43. Pathak, A. K. (2012): Anti-Candida of Aqueous Extract of Some Herbals. Indian Journal of Fundamental and Applied Life Sciences, 2 (2): 1-6.
44. Peer, A. K., Hoosen, A. A. and Seedat, M. A. (1993): Vaginal yeast infections in diabetic women. S Afr Med J., 83:727-729.
45. Pesewu, G. A., Cutler, R. R. and Humber, D. P. (2008): Antibacterial activity of plants used in traditional medicines of Ghana with particular reference to MRSA. J. Ethnopharmacol., 116: 102-111.
46. Radmila, R. O., Ljiljana, G. K., Ana N. P., Milica, S. P., Nikola, D. Z. and Dusan M. Z. (2011): Diabetes mellitus and oral candidiasis. Acta Stomatologica Naissi, 27 (63): 1024-1034.
47. Rindum, J. L., Stenderup, A. and Holmstrup, P. (1994): Identification of *Candida albicans* types related to healthy and pathological oral mucosa. J Oral Pathol Med., 23: 406- 412.
48. Rukayadi, Y., Yong, D. and Hwangy, J. (2006): In Vitro Anticandidal Activity of Xanthorrhizol Isolated from *Curuma xanthorriza* *roxb*, Antimicrob chemother, 57 (6): 237-234.
49. Ruping, M. J., Vehreschild, J. J. and Cornely, O. A. (2008): Patients at high risk of invasive fungal infections: when and how to treat. Drugs, 68: 1941-1962.
50. Salari, M. H., Amine, G., Shirazi, M. H., Hafezi, R. and Mohammadypour, M. (2006): Antibacterial effects of *Eucalyptus globulus* leaf extract on pathogenic bacteria isolated from specimens of patients with respiratory tract disorders. Clin Microbiol Infect., 12: 194-196.
51. Samaranayake, L. P. and Leung W. K. (2000): Oral mucosal fungal infections. Periodontology, 49 (1): 39–59.
52. Sashikumar, R and Kannan, R. (2010): Salivary glucose levels and oral candidal carriage in type II diabetics. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology, 109 (5): 706-711.
53. Senhaji, O., Faid, M. and Kalalou, I. (2007): Inactivation of *Escherichia coli* O157:H7 by essential oil from *Cinnamomum zeylanicum*. Braz J Infect Dis., 11: 234-236.
54. Taschdjian, C. L. (1957): Routine identification of *Candida albicans*: current methods on a new medium. Mycologia., 49: 332–338.
55. Thompson, G. R., Patel, P. K., Kirkpatrick, W. R., Westbrook, S. D., Berg, D. and Erlandsen, J. (2010): Oropharyngeal candidiasis in the era of antiretroviral therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod., 109: 488-495.

12/1/2014